Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer
Cancer Treatment and Research Communications · 2026 · 49 · 101503
DOI: 10.1016/j.ctarc.2026.101503 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Jian Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhejiang Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Zhejiang University of Chinese Medicine, H…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Zhejiang Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou, 310000, Zhejiang, China.
- Department of Oncology, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, 310000, China. Electronic address: guoyong1047@zcmu.edu.cn.
Zitieren
APA
Zheng, J., Chi, L., & Guo, Y. (2026). Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer. Cancer Treatment and Research Communications, 49, 101503. https://doi.org/10.1016/j.ctarc.2026.101503
Vancouver
Zheng J, Chi L, Guo Y. Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer. Cancer Treatment and Research Communications. 2026;49:101503. doi:10.1016/j.ctarc.2026.101503
BibTeX
@article{Zheng2026,
author = {Zheng, Jian and Chi, Luyang and Guo, Yong},
title = {Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101503},
doi = {10.1016/j.ctarc.2026.101503}
}
EUVIMED